Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,501–1,600 of 2,517
Stoner, C. S., Pearson, G. D., Koç, A., Merwin, J. R., Lopez, N. I., & Merrill, G. F. (2009) · Biochemistry · doi:10.1021/bi900757q · Cited by 20
“motif (24), it was possible that serine replacement at these positions was deleterious to p53 activity due to destabilization of native structure.”
BackgroundInfluentialHuang, W., & Bateman, E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28839 · Cited by 18
The diversity of p53 mutations among human brain tumors and their functional consequences
Żupańska, A. K., & Kaminska, B. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00114-0 · Cited by 18
Balakrishnan, S. K., & Gross, D. S. (2007) · Oncogene · doi:10.1038/sj.onc.1210935 · Cited by 19
“Its importance in preventing malignancy is indicated by the fact that 50% of analysed human tumors bear mutations in p53, with 97% mapping to p53’s core DNA-binding domain (Cho et al., 1994).”
BackgroundFATS is a transcriptional target of p53 and associated with antitumor activity
Zhang, X., Zhang, Q., Zhang, J., Qiu, L., Yan, S.-S., Feng, J., Sun, Y. K., Huang, X., Lu, K. H., & Li, Z. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-244 · Cited by 18
“In consensus motif of p53-RE, the most important bases for interactions with the p53 protein are the central CWWG nucleotides within each half-site, especially the C and G [3,9].”
BackgroundRapid sequencing of the p53 gene with a new automated DNA sequencer
BHARAJ, B. S., Angelopoulou, K., & Diamandis, E. P. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.7.1397 · Cited by 18
“Clinical Chemistry 44:7 1397–1403 (1998) Molecular Diagnostics and Genetics 1397 D ow nloaded from https://academ ic.oup.com /clinchem /article-abstract/44/7/1397/5642769 by guest on 01 February 2020 R282 (8), which play a vital role in the structural integrity of the DNA-binding domain.”
BackgroundInfluentialp53 Amino Acids 339–346 Represent the Minimal p53 Repression Domain
Hong, T.-M., Chen, J. J. W., Peck, K., Yang, P., & Wu, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008231200 · Cited by 17
Kyndi, M., Alsner, J., Hansen, L. L., et al. (2006) · Acta Oncologica · doi:10.1080/02841860600660811 · Cited by 18
“The site is located in a hydrophobic region of the TP53 gene (between amino acids 61 and 94) [4].”
BackgroundTang, R., Wang, J., Lo, S. K., & Hsieh, L. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990812)82:4<473::aid-ijc1>3.0.co;2-k · Cited by 70
Lassus, P., Bertrand‐Gaday, C., Zugasti, O., Chambon, J., Soussi, T., Mathieu-Mahul, D., & Hibner, U. (1999) · Oncogene · doi:10.1038/sj.onc.1202841 · Cited by 20
“The tertiary structure of the mutant protein is predicted to be profoundly altered by this substitution (Cho et al., 1994) and, indeed, this compromises many activities of wild type p53 (Friedlander et al., 1996; Ory et al., 1994).”
BackgroundLebrun, A., Lavery, R., & Weinstein, H. (2001) · Protein Engineering, Design and Selection · doi:10.1093/protein/14.4.233 · Cited by 18
“Inspection of the monomeric p53DBD–DNA crystal structure shows that the monomer interacts not only with the five base pairs AGGCT, but also with some of the quasisymmetric ones (Cho et al., 1994).”
BackgroundMethodResultInfluentialAl-Masawa, M. E., Zaman, W. S. W. K., & Chua, K. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-78395-y · Cited by 17
Timofeev, O. N., & Stiewe, T. (2021) · Cancers · doi:10.3390/cancers13102422 · Cited by 19
“The loop-sheet-helix motif that includes the L1 loop binds the minor groove, whereas the L2 and L3 loops, stabilized by a zinc ion, dock to the major groove [31,38].”
BackgroundInfluentialDesigned Ankyrin Repeat Proteins as a tool box for analyzing p63
Strubel, A., Münick, P., Chaikuad, A., Dreier, B., Schaefer, J. V., Gebel, J., Osterburg, C., Tuppi, M., Schäfer, B., Knapp, S., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01030-y · Cited by 18
“The loop L1 that in p53 provides an additional contact via K120 [39] (conserved in p63), which however is not essential for DNA binding [40], interacts with the non-randomized scaffold of the DARPins, resulting in steric hindrance but no speci fi c interaction.”
BackgroundPal, A., Gonzalez-Malerva, L. G., Eaton, S., Xu, C., Zhang, Y., Grief, D., Sakala, L., Nwekwo, L., Zeng, J., Christensen, G., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00582-7 · Cited by 22
Pyrazolone-Based Zn(II) Complexes Display Antitumor Effects in Mutant p53-Carrying Cancer Cells
Xhafa, S., Nicola, C. D., Tombesi, A., Pettinari, R., Pettinari, C., Scarpelli, F., Crispini, A., Deda, M. L., Candreva, A., Garufi, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01298 · Cited by 20
The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma
Karsy, M. J., Albert, L., Murali, R., & Jhanwar‐Uniyal, M. (2014) · Tumor Biology · doi:10.1007/s13277-013-1601-6 · Cited by 20
The human papillomavirus type 16 E7 oncoprotein targets Myc-interacting zinc-finger protein-1
Morandell, D., Kaiser, A. M., Herold, S., et al. (2011) · Virology · doi:10.1016/j.virol.2011.10.027 · Cited by 17
“, 1991), resulting in loss of DNA binding (Cho et al., 1994).”
BackgroundLi, X., Ottosson, S., Wang, S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1356-0 · Cited by 17
“transcription [33].”
Dorszewska, J., Oczkowska, A., Suwalska, M., Różycka, A., Florczak‐Wyspianska, J., Dezor, M., Lianeri, M., Jagodziński, P. P., Kowalczyk, M. J., Prendecki, M., et al. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.41742 · Cited by 20
“Cys235 and Cys239, along with Cys173 and His176, coordinate a zinc atom forming a structure crucial for DNA binding [11,47].”
Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer
Dimas-González, J., Lagunas, V. M., Díaz‐Chávez, J., López‐Arellano, M. E., MUÑOZ-CAMACHO, J. G., Terán-Porcayo, M. A., & Lagunas-Martínez, A. (2017) · Oncology Reports · doi:10.3892/or.2017.5553 · Cited by 17
Raman Evidence of p53-DBD Disorder Decrease upon Interaction with the Anticancer Protein Azurin
Signorelli, S., Cannistraro, S., & Bizzarri, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123078 · Cited by 17
“Moreover, Tyr126 and Tyr205, located at a crucial protein region interfacing with the DNA, show moderate accessibility, similar to that of Tyr220 located on the surface of the protein [7,8].”
BackgroundTang, Y., Yao, Y., & Wei, G. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c05638 · Cited by 18
Prowald, A., Cronauer, M. V., von Klot, C. A. J., Eilers, T., Rinnab, L. J., Herrmann, T. W., Spindler, K., Montenarh, M., Udo Jonas, A., & Burchardt, M. (2007) · The Prostate · doi:10.1002/pros.20660 · Cited by 18
“While p53 is a DNA-contact mutant unable to specifically bind DNA [17], p53 and p53 belong to the group of structural p53 mutants, where the direct DNA contact is not affected.”
BackgroundStudies of interaction of tumor suppressor p53 with apo-MT using surface plasmon resonance
Xia, N., Liu, L., Yi, X., & Wang, J. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-3174-1 · Cited by 17
Liu, X., Tian, W., Cheng, J., Li, D., Liu, T., & Zhang, L. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107194 · Cited by 17
Calculation of Symmetric Oligomer Structures from NMR Data
O'Donoghue, S., & Nilges, M. (2002) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47084-5_4 · Cited by 17
Gorlov, I. P., Gorlova, O. Y., Frazier, M. L., & Amos, C. I. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.04.014 · Cited by 17
The contribution of the Trp/Met/Phe residues to physical interactions of p53 with cellular proteins
Ma, B., Pan, Y., Gunasekaran, K., Keskin, Ö., Venkataraghavan, R. B., Levine, A. J., & Nussinov, R. (2005) · Physical Biology · doi:10.1088/1478-3975/2/2/s06 · Cited by 19
“Phe212 contributes to the p53–p53 core domain dimeric interactions observed in the p53–DNA complex [49].”
BackgroundShao, J., Ji-feng, W., Wang, D.-B., Qin, R., & Zhang, H. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i3.427 · Cited by 17
Speiser, P., Gharehbaghi-Schnell, E., Eder, S., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.350 · Cited by 17
p53 Mutations and DNA Ploidy in Colorectal Adenocarcinomas
Campomenosi, P., Assereto, P., Bogliolo, M., Fronza, G., Abbondandolo, A., Capasso, A., Bellomo, P. F., Monaco, R., Rapallo, A., Sciutto, A., et al. (1998) · Analytical Cellular Pathology · doi:10.1155/1998/396371 · Cited by 17
“More than 90% of known p53 mutations reported so far in human tumours occur in this region [28], corresponding to the core of the protein involved in sequence specific DNA binding [14].”
BackgroundMolecular diagnosis of p53 mutations in gastric carcinoma by touch preparation.
Ricevuto, E., Ficorella, C., Fusco, C., Cannita, K., Tessitore, A., Toniato, E., Gabriele, A., Frati, L., Marchetti, P., Gulino, A., et al. (1996) · Europe PMC (PubMed Central) · Cited by 18
Wen, W., Zhang, W., Tan, R., Zhong, T.-T., Zhang, M.-R., & Fang, X. (2024) · American Journal of Cancer Research · doi:10.62347/lhio8294 · Cited by 18
Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis
Soond, S. M., Savvateeva, L. V., Makarov, V. A., Gorokhovets, N. V., Townsend, P. A., & Zamyatnin, A. A. (2020) · Cancers · doi:10.3390/cancers12113476 · Cited by 18
“Based on the growing numbers of such mutated gene products, they can be classified as “contact” or “structural” mutations (based on alterations in their DNA-binding ability), such as the contact mutants R248W, R273C, and R73C [83] and the structural mutants R175H [85,86], R282W, [87], and Y220C [88].”
BackgroundProtein of a thousand faces: The tumor-suppressive and oncogenic responses of p53
Marques, M. A., de Andrade, G. C., Silva, J. L., & de Oliveira, G. A. P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.944955 · Cited by 16
“Molecular models of the crosslinked p53DBD-DNA complex revealed p53 tetramers interacting with two REs (Cho et al., 1994).”
BackgroundMartin, J. C., Fadda, E., Ito, K., & Woods, R. J. (2013) · Glycobiology · doi:10.1093/glycob/cwt094 · Cited by 20
“…the crystallographic and MD-derived conformations of the p53 glycopeptides with the crystal structure of the full-length p53 protein (PDBid 1TUP) (Cho et al. 1994), indicated that the W146 orientation from the MD results was in good agreement with the conformation seen in the intact p53 protein…”
ResultInfluentialEvaluating Drosophila p53 as a Model System for Studying Cancer Mutations
Herzog, G., Joerger, A. C., Shmueli, M. D., Fersht, A. R., Gazit, E., & Segal, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417980 · Cited by 19
Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer
Betancor-Fernández, I., Timson, D. J., SALIDO, E. C., & Pey, A. L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_55 · Cited by 17
Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
Ahn, S. G., Yoon, C. I., Lee, J., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0281 · Cited by 16
Omar, S. I., & Tuszyński, J. A. (2018) · Oncotarget · doi:10.18632/oncotarget.26440 · Cited by 15
“We used chain B of the p53-DNA complex 1TSR [21] PDB structure to create our models.”
MethodMotlagh, A. V., Mahdevar, M., Mirzaei, S., Entezari, M., Hashemi, M., Hushmandi, K., & Peymani, M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120650 · Cited by 18
Nurhayati, A. P. D., Rihandoko, A., Fadlan, A., Ghaissani, S. S., Jadid, N., & Setiawan, E. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.06.012 · Cited by 21
“Protein structures were taken from the RCSB Protein Data Bank database (Burley et al., 2019) with PDB ID: 2UZE for cdk-2 (Richardson et al., 2007), 1TUP for p53 (Cho et al., 1994), and 1NW9 for caspase-9 (Shiozaki et al., 2003).”
Porrello, A., Soddu, S., Zbilut, J. P., Crescenzi, M., & Giuliani, A. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20075 · Cited by 17
“…mentioned p53 mutations of the residues directly involved in the DNA-protein contacts and those affecting the correct folding of the p53 DBD. 27 This result suggests that RQA is an appropriate tool for the development of a comprehensive p53 database, characterized by information about the…”
MethodResultInfluentialWallentine, B. D., Wang, Y., Tretyachenko-Ladokhina, V., Tan, M., Senear, D. F., & Luecke, H. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913020830 · Cited by 15
“The core domain consists of a -sandwich scaffold which defines the DNA-binding surface (Cho et al., 1994).”
BackgroundInfluentialThe Tetramer of p53 in the Absence of DNA Forms a Relaxed Quaternary State
Pham, N., Lucumi, A., Cheung, N., & Viadiu, H. (2012) · Biochemistry · doi:10.1021/bi301193k · Cited by 16
Wu, H., Hyun, J.-S., Martinez‐Yamout, M. A., Park, S. J., & Dyson, H. J. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01076 · Cited by 15
“Nature of the Interaction between p53(88-312) and p23(1-160)”
BackgroundMethodResultInfluentialVirtual Screening Based on Ensemble Docking Targeting Wild‐Type p53 for Anticancer Drug Discovery
Li, X., Zhang, X., Lin, Y., Xu, X., Li, L., & Yang, J. B. (2019) · Chemistry & Biodiversity · doi:10.1002/cbdv.201900170 · Cited by 18
The Role of Protein Structural Analysis in the Next Generation Sequencing Era
Yue, W. W., Froese, D. S., & Brennan, P. E. (2012) · Topics in current chemistry · doi:10.1007/128_2012_326 · Cited by 18
Fimognari, C., Sangiorgi, L., Capponcelli, S., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-6727-y · Cited by 16
“protein interior, suggesting that mutation of this residue would destabilize the folder state of the protein [27].”
BackgroundIdentification of the regions involved in DNA binding by the mouse PEBP2α protein
Pérez-Alvarado, G. C., Munnerlyn, A., Dyson, H. J., Grosschedl, R., & Wright, P. E. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01296-5 · Cited by 16
p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma
Runnebaum, I. B., Köhler, T., Stickeler, E., Kieback, H., & Kreienberg, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.510 · Cited by 15
Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo
Ponchel, F., & Milner, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.256 · Cited by 15
The Role of the p53 Tumour Suppressor Gene in Human Breast Cancer
Phillips, H. A. (1999) · Clinical Oncology · doi:10.1053/clon.1999.9032 · Cited by 16
Biological significance and molecular mechanisms of p53-induced apoptosis
Bedi, A., & Mookerjee, B. (1998) · APOPTOSIS · doi:10.1023/a:1009648824027 · Cited by 17
Wacey, A. I., Cooper, D. N., Liney, D., et al. (1999) · Human Genetics · doi:10.1007/s004390050904 · Cited by 16
“Molecular characteristics of amino acid substitutions in p53 The crystallographic structure of human p53 (Cho et al. 1994) was read into the Biopolymer module of Biosym 95.0 (MSI, Cambridge, UK) and the DNA moiety removed in order to approximate the folded protein conformation prior to DNA binding…”
BackgroundMethodInfluentialStructural assessment of single amino acid mutations: application to TP53 function
Yip, Y. L., Zoete, V., Scheib, H., & Michielin, O. A. (2006) · Human Mutation · doi:10.1002/humu.20379 · Cited by 16
“These mutations can be classified into two major types: 1) contact mutations with only minor effects on folding and stability; and 2) mutations that affect stability and cause unfolding of the DNA-binding domain [Cho et al., 1994; Hainaut and Hollstein, 2000].”
BackgroundMethodCOMMENTARY: Mutational spectra: from model systems to cancer-related genes
Dogliotti, E. (1996) · Carcinogenesis · doi:10.1093/carcin/17.10.2113 · Cited by 19
Horio, Y., Chen, A., Rice, P., Roth, J. A., Malkinson, A. M., & Schrump, D. S. (1996) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199612)17:4<217::aid-mc5>3.0.co;2-a · Cited by 103
Identification of novel p53 target genes by cDNA AFLP in glioblastoma cells
Saffari, M., Dinehkabodi, O. S., Ghaffari, S. H., Modarressi, M. H., Mansouri, F., & Heidari, M. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.08.020 · Cited by 15
“p53 tumor suppressor gene is a well-known transcription factor that modulates numerous genes involved in many cellular functions such as cell cycle arrest, induction of apoptosis, and anti-angiogenesis [1,2].”
BackgroundWhat do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
“Six ‘hotspot’ residues are mutated within the DNA-binding domain (R175, G245, R248, R249, R273, and R282) that affect its interaction with DNA either directly or indirectly by disrupting the structure of p53 protein [30].”
BackgroundCavagna, R. D. O., Pinto, I. A., de Paula, F. E., Berardinelli, G. N., Sant'Anna, D., Santana, I. V. V., da Silva, V. D., da Silva, E. C. A., Miziara, J. E., Dias, J. M., et al. (2022) · Brazilian Journal of Oncology · doi:10.1055/s-0044-1795525 · Cited by 16
Liu, X., Xia, Z., Wang, Y., Luo, D., Li, Z., Meng, Z., & Lian, H. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102393 · Cited by 30
Effect of Metal Ion on the Structural Stability of Tumour Suppressor Protein p53 DNA-Binding Domain
Xue, Y., Wang, S., & Feng, X. (2009) · The Journal of Biochemistry · doi:10.1093/jb/mvp055 · Cited by 15
Schaefer, K. N., Geil, W. M., Sweredoski, M. J., Moradian, A., Hess, S. Y., & Barton, J. K. (2015) · Biochemistry · doi:10.1021/bi501424v · Cited by 16
Cheng, Z., Zhu, S., Wang, L., Liu, F., Tian, H., Pengsakul, T., & Wang, Y. (2015) · International Journal for Parasitology · doi:10.1016/j.ijpara.2015.02.010 · Cited by 18
“The structure of the DNA-binding domain of human p53 (residues 94–292) (Protein Data Bank (PDB) code 1TSR) (Cho et al., 1994) is shown, with sites of cancer hotspot mutations and essential DNA contacts shown as stick models (adapted from Joerger and Fersht (2010) with permission from Cold Spring Harbor Laboratory Pres…”
BackgroundMethodInfluentialAccuracy and Reproducibility of Protein–DNA Microarray Technology
Field, S., Udalova, I. A., & Ragoussis, J. (2006) · Springer eBooks · doi:10.1007/10_2006_035 · Cited by 15
The novel p53 isoform “delta p53” is a misfolded protein and does not bind the p21 promoter site
García-Alai, M., Tidow, H., Natan, E., Townsley, F. M., Veprintsev, D. B., & Fersht, A. R. (2008) · Protein Science · doi:10.1110/ps.036996.108 · Cited by 15
Redox state of p63 and p73 core domains regulates sequence-specific DNA binding
Tichý, V., Navrátilová, L., Adámik, M., Fojta, M., & Brázdová, M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.097 · Cited by 15
Lipomatous hemangiopericytoma of the head and neck: immunohistochemical and dna ploidy analyses
Alrawi, S., Deeb, G., Cheney, R., et al. (2004) · Head & Neck · doi:10.1002/hed.20054 · Cited by 15
Suchánková, J., Legartová, S., Růčková, E., Vojtěšek, B., Kozubek, S., & Bártová, E. (2017) · Histochemistry and Cell Biology · doi:10.1007/s00418-017-1567-3 · Cited by 16
Curtin, J. C., & Spinella, M. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208130 · Cited by 16
“This region is part of a fully folded independent domain of unknown function (Bargonetti et al., 1993; Pavletich et al., 1993; Cho et al., 1994).”
BackgroundMartínez, R., Schackert, H., von Kannen, S., et al. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00488.x · Cited by 15
Influence of Magnesium Ion on the Binding of p53 DNA-Binding Domain to DNA-Response Elements
Xue, Y., Wang, S., & Feng, X. (2009) · The Journal of Biochemistry · doi:10.1093/jb/mvp048 · Cited by 15
Russo, A. D., Corsale, S., Agnese, V., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20447 · Cited by 15
“…types of tumors have shown that most of the TP53 mutations affect exons 5–8, which code for residues 130–286, the most important region for the folding and the stabilization of the tertiary structure of the protein, and which contains the site-specific, DNAbinding domain (Cho et al., 1994).”
BackgroundMitsuhashi, A., Tanaka, H., Tanaka, N., et al. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5072 · Cited by 15
Jenkins, G. J. S., Mitchell, I. D. G., & Parry, J. M. (1997) · Mutagenesis · doi:10.1093/mutage/12.3.117 · Cited by 16
“Exon 5 lies in the second evolutionary conserved region (Soussi et al, 1990) which is involved in DNA binding (Cho et al, 1994).”
BackgroundHo, Y., Cheng, H., Wang, Y., et al. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130308 · Cited by 15
Kohler, U., & Allemann, R. K. (2002) · Wiley eBooks · doi:10.1002/047120918x.emb1569 · Cited by 15
Zhang, Q., Balourdas, D.-I., Baron, B., Senitzki, A., Haran, T. E., Wiman, K. G., Soussi, T., & Joerger, A. C. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04653-8 · Cited by 14
Behery, M. E., Abo–Elmatty, D. M., Alsunbul, M., El-Deen, Y. I. M., Mohamed, D. I., Sindi, E. R., Hashem, M. H., Al-Olayan, E. M., Ibrahim, I. A. A., Bamagous, G. A., et al. (2025) · RSC Advances · doi:10.1039/d5ra01014d · Cited by 17
Malik, M. A., Raza, M. K., Mohammed, A., Wani, M. Y., Al‐Bogami, A. S., & Hashmi, A. A. (2021) · RSC Advances · doi:10.1039/d1ra06227a · Cited by 14
Metal-Based Anticancer Complexes and p53: How Much Do We Know?
Alfadul, S. M., Matnurov, E. M., Varakutin, A. E., & Babak, M. V. (2023) · Cancers · doi:10.3390/cancers15102834 · Cited by 16
“used a recombinant p53 protein which was obtained from PA1620 and PAb240 antibodies [39].”
BackgroundMethodInfluentialAntineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Kusuma, S. S., Tanneeru, K., Didla, S., Devendra, B. N., & Patnala, K. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520614666140715085907 · Cited by 16
“63 is observed and these residues are believed to be present in between 102 – 292 which is the core domain reported for possible mutation [9].”
BackgroundBromley, D., Bauer, M. R., Fersht, A. R., & Daggett, V. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw035 · Cited by 16
“These mutations can be broken out into two general categories: ‘contact’ mutations that alter DNA binding, and ‘structural’ mutations that affect the protein’s structural integrity (Cho et al. 1994).”
BackgroundBuhr, C. R., Eckrich, J., Kluenker, M., Bruns, K., Wiesmann, N., Tremel, W., & Brieger, J. (2021) · Nanotoxicology · doi:10.1080/17435390.2021.1916635 · Cited by 15
Carlsson, J., Soussi, T., & Persson, B. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07124.x · Cited by 16
“The three-dimensional structure of p53 was taken from the PDB entry 1tsr chain 1 [25] in the RCSB protein data bank (http://www.pdb.org), as a basis for all measurements and simulations.”
MethodNakagawa, S., Yoshikawa, H., Jimbo, H., Onda, T., Yasugi, T., Matsumoto, K., Kino, N., Kawana, K., Kozuka, T., Nakagawa, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690181 · Cited by 14
“The majority of the missense mutations occur in the central DNA-binding domain, especially in the conserved regions across species, that are exon 5Ð8 (Cho et al, 1994).”
BackgroundInfluentialLinking up and interacting with BRCT domains
Watts, F. Z., & Brissett, N. C. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.10.010 · Cited by 17
Millau, J., Bandele, O. J., Perron, J., Bastien, N., Bouchard, É. F., Gaudreau, L. R., Bell, D. A., & Drouin, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1209 · Cited by 17
“A non-binding sequence (negative controlWRNC) and a positive binding sequence [positive control ConC GGGCAA GTCTGGGCAAGTCT, which is a perfect match with the p53 consensus RE (25,26)] were examined in each reaction, untreated cells served as a negative control.”
A novel case with germline p53 gene mutation having concurrent multiple primary colon tumours
Miyaki, M., Iijima, T., Ohue, M., Kita, Y., Hishima, T., Kuroki, T., Iwama, T., & Mori, T. (2003) · Gut · doi:10.1136/gut.52.2.304 · Cited by 15
Comparative assessment of the functional p53 status in glioma cells.
Kim, E. L., Yoshizato, K., Kluwe, L., Meissner, H., Warnecke, G., Zapf, S., Westphal, M., Deppert, W., & Giese, A. (2005) · PubMed · Cited by 16
The p53 Tumor Suppressor Gene: Structure, Function and Mechanism of Action
Choisy, C., Reisdorf, P., & Yonish-Rouach, E. (1999) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69184-6_8 · Cited by 19
Bizzarri, A. R., Agostino, S. D., Andolfi, L., & Cannistraro, S. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.975 · Cited by 14
Capponcelli, S., Pedrini, E., Cerone, M. A., Corti, V., Fontanesi, S., Alessio, M., Bachi, A., Soddu, S., Ribatti, D., Picci, P., et al. (2005) · Human Mutation · doi:10.1002/humu.20192 · Cited by 15
“…in which p53 mutations were divided into two classes: those located in the DNA contact area were termed class I, and those that occur in areas that are important for stability (e.g., the L2 loop) and lead to conformational changes were termed class II [e.g., Cho et al., 1994; Wong et al., 1999].”
BackgroundIntronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response
Vishnupriya, S., Sailaja, K., Rao, V., et al. (2012) · Journal of Natural Science Biology and Medicine · doi:10.4103/0976-9668.101910 · Cited by 14
“[4,5] The majority of both sporadic and germline TP53 mutations found in cancer cells were missense point mutations, occurring mainly in the DNA binding domain of the protein.[6] P53 is a highly conserved gene and exons 5–8 contain four of the five evolutionary conserved domains of p53 gene encoding amino acids 117–28…”
BackgroundEspinoza-Fonseca, M., & Trujillo-Ferrara, J. G. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.129 · Cited by 14
Wubah, J. A., Setzer, R. W., Lau, C. S., et al. (2001) · Teratology · doi:10.1002/tera.1059 · Cited by 14
Wang, P. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000584 · Cited by 15
Coomber, D., & Ward, R. L. (2001) · PubMed · Cited by 14
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.